Physician profile
Dyna M Cross
NPI 1750013959
$857.71
in general payments reported to CMS, 2019-2025
17 companies · $21.03 in 2025
The $21.03 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $53.11 · 2023: $763 · 2024: $20.09 · 2025: $21.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $189.86 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.85 | 2023 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $74.70 | 2023 | Stelara |
| Qol Medical, LLC | $65.36 | 2023 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $59.64 | 2023 | Entyvio |
| Genzyme Corporation | $44.88 | 2023 | |
| Celgene Corporation | $39.83 | 2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $29.30 | 2023 | Dupixent |
| Amgen INC. | $28.35 | 2023 | Avsola, Amjevita |
| Gilead Sciences, INC. | $25.04 | 2023 | Epclusa |
| Intercept Pharmaceuticals, INC. | $22.48 | 2023 | Ocaliva |
| Boston Scientific Corporation | $21.03 | 2025 | Spyglass Discover |
| Conmed Corporation | $20.09 | 2024 | Airseal |
| Nestle Healthcare Nutrition INC. | $19.86 | 2023 | |
| Merck Sharp & Dohme LLC | $18.93 | 2023 | Dificid |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $17.20 | 2023 | |
| Ardelyx, INC. | $13.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dyna Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.